Business Description
Summit Therapeutics PLC
NAICS : 541714
SIC : 2833
ISIN : GB00BN40HZ01
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.99 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.56 | |||||
Debt-to-EBITDA | -0.74 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -9.7 | |||||
3-Year EPS without NRI Growth Rate | 41.3 | |||||
3-Year FCF Growth Rate | 43.8 | |||||
3-Year Book Growth Rate | -51.3 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | 29.41 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.35 | |||||
Quick Ratio | 2.35 | |||||
Cash Ratio | 2.32 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -104.1 | |||||
Shareholder Yield % | 0.46 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -150.85 | |||||
ROA % | -68.66 | |||||
ROIC % | -234.51 | |||||
3-Year ROIIC % | 820.34 | |||||
ROC (Joel Greenblatt) % | -1950.73 | |||||
ROCE % | -86.34 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 84.35 | |||||
EV-to-EBIT | -108.62 | |||||
EV-to-EBITDA | -110.07 | |||||
EV-to-FCF | -166.2 | |||||
Earnings Yield (Greenblatt) % | -0.92 | |||||
FCF Yield % | -0.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Summit Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | 0 | ||
Beta | 0 | ||
Volatility % | 78.83 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 0 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 0.17 - 0.36 | ||
Shares Outstanding (Mil) | 336.16 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Summit Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Summit Therapeutics PLC Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Summit Therapeutics PLC Frequently Asked Questions
What is Summit Therapeutics PLC(FRA:UVF1)'s stock price today?
When is next earnings date of Summit Therapeutics PLC(FRA:UVF1)?
Does Summit Therapeutics PLC(FRA:UVF1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |